tiprankstipranks
Innovent Biologics (MX:1801N)
:1801N
Mexico Market
1801N
Innovent Biologics
RESEARCH TOOLSreports

Innovent Biologics (1801N) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

1801N Analyst Ratings

Strong Buy
20Ratings
Strong Buy
20 Buy
0 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Innovent
Biologics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1801N Stock 12 Month Forecast

Average Price Target

―
Based on 20 Wall Street analysts offering 12 month price targets for Innovent Biologics in the last 3 months. The average price target is $288.92 with a high forecast of $325.29 and a low forecast of $242.52. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$325.29Average Price Target$288.92Lowest Price Target$242.52
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
DBS Analyst forecast on MX:1801N
Mark Kong CFA
DBS
DBS
$311.81
Buy
―
Reiterated
09/15/26
Analysts Offer Insights on Healthcare Companies: Innovent Biologics (Other OTC: IVBXF) and Definium Therapeutics (NASDAQ: DFTX)
Huatai Securities Analyst forecast on MX:1801N
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
$280.49
Buy
―
Reiterated
09/12/26
Huatai Securities Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
UBS Analyst forecast on MX:1801N
Unknown Analyst
UBS
Not Ranked
UBS
$268.72→$292.97
Buy
―
Reiterated
09/02/26
UBS Keeps Their Buy Rating on Innovent Biologics (IVBXF)
BOCOM International Holdings Company Analyst forecast on MX:1801N
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
$255.51→$279.33
Buy
―
Reiterated
09/02/26
BOCOM International Holdings Company Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CSC Financial Analyst forecast on MX:1801N
Unknown Analyst
CSC Financial
Not Ranked
CSC Financial
$319.82→$321.2
Buy
―
Reiterated
08/28/26
Analysts Are Bullish on Top Healthcare Stocks: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990), Innovent Biologics (IVBXF)
Citi Analyst forecast on MX:1801N
Unknown Analyst
Citi
Not Ranked
Citi
$249.01→$323.93
Buy
―
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from Citi
Jefferies Analyst forecast on MX:1801N
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$270.66
Buy
―
Reiterated
08/27/26
Jefferies Remains a Buy on Innovent Biologics (IVBXF)
J.P. Morgan Analyst forecast on MX:1801N
Yang Huang
J.P. Morgan
J.P. Morgan
$253.34→$303.14
Buy
―
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from J.P. Morgan
CMB International Securities Analyst forecast on MX:1801N
Jill Wu
CMB International Securities
CMB International Securities
$282.03
Buy
―
Reiterated
08/27/26
Analyst Jill Wu Raises Target Price and Reiterates Buy on Innovent Biologics After Strong 1H26 Beat and Robust Growth Outlook
Bank of America Securities Analyst forecast on MX:1801N
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
$303.14
Buy
―
Reiterated
08/26/26
Bank of America Securities Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CLSA Analyst forecast on MX:1801N
Unknown Analyst
CLSA
Not Ranked
CLSA
$302.93→$316.35
Buy
―
Reiterated
08/26/26
Innovent Biologics (IVBXF) Receives a Buy from CLSA
Daiwa Analyst forecast on MX:1801N
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$259.84→$292.32
Buy
―
Reiterated
08/26/26
Innovent Biologics (IVBXF) Gets a Buy from Daiwa
CICC Analyst forecast on MX:1801N
Unknown Analyst
CICC
Not Ranked
CICC
$256.16
Buy
―
Reiterated
08/26/26
CICC Remains a Buy on Innovent Biologics (IVBXF)
Morgan Stanley Analyst forecast on MX:1801N
Jack Lin
Morgan Stanley
Morgan Stanley
$299.9
Buy
―
Reiterated
08/25/26
Jack Lin Reiterates Buy on Innovent Biologics, Citing Strong Profitability, Solid Revenue Growth, and De-Risked Late-Stage Pipeline
Guotai Haitong Analyst forecast on MX:1801N
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$259.38
Buy
―
Reiterated
08/25/26
Guotai Haitong Remains a Buy on Innovent Biologics (IVBXF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
DBS Analyst forecast on MX:1801N
Mark Kong CFA
DBS
DBS
$311.81
Buy
―
Reiterated
09/15/26
Analysts Offer Insights on Healthcare Companies: Innovent Biologics (Other OTC: IVBXF) and Definium Therapeutics (NASDAQ: DFTX)
Huatai Securities Analyst forecast on MX:1801N
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
$280.49
Buy
―
Reiterated
09/12/26
Huatai Securities Sticks to Their Buy Rating for Innovent Biologics (IVBXF)
UBS Analyst forecast on MX:1801N
Unknown Analyst
UBS
Not Ranked
UBS
$268.72→$292.97
Buy
―
Reiterated
09/02/26
UBS Keeps Their Buy Rating on Innovent Biologics (IVBXF)
BOCOM International Holdings Company Analyst forecast on MX:1801N
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
$255.51→$279.33
Buy
―
Reiterated
09/02/26
BOCOM International Holdings Company Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CSC Financial Analyst forecast on MX:1801N
Unknown Analyst
CSC Financial
Not Ranked
CSC Financial
$319.82→$321.2
Buy
―
Reiterated
08/28/26
Analysts Are Bullish on Top Healthcare Stocks: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990), Innovent Biologics (IVBXF)
Citi Analyst forecast on MX:1801N
Unknown Analyst
Citi
Not Ranked
Citi
$249.01→$323.93
Buy
―
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from Citi
Jefferies Analyst forecast on MX:1801N
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$270.66
Buy
―
Reiterated
08/27/26
Jefferies Remains a Buy on Innovent Biologics (IVBXF)
J.P. Morgan Analyst forecast on MX:1801N
Yang Huang
J.P. Morgan
J.P. Morgan
$253.34→$303.14
Buy
―
Reiterated
08/27/26
Innovent Biologics (IVBXF) Receives a Buy from J.P. Morgan
CMB International Securities Analyst forecast on MX:1801N
Jill Wu
CMB International Securities
CMB International Securities
$282.03
Buy
―
Reiterated
08/27/26
Analyst Jill Wu Raises Target Price and Reiterates Buy on Innovent Biologics After Strong 1H26 Beat and Robust Growth Outlook
Bank of America Securities Analyst forecast on MX:1801N
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
$303.14
Buy
―
Reiterated
08/26/26
Bank of America Securities Reaffirms Their Buy Rating on Innovent Biologics (IVBXF)
CLSA Analyst forecast on MX:1801N
Unknown Analyst
CLSA
Not Ranked
CLSA
$302.93→$316.35
Buy
―
Reiterated
08/26/26
Innovent Biologics (IVBXF) Receives a Buy from CLSA
Daiwa Analyst forecast on MX:1801N
Unknown Analyst
Daiwa
Not Ranked
Daiwa
$259.84→$292.32
Buy
―
Reiterated
08/26/26
Innovent Biologics (IVBXF) Gets a Buy from Daiwa
CICC Analyst forecast on MX:1801N
Unknown Analyst
CICC
Not Ranked
CICC
$256.16
Buy
―
Reiterated
08/26/26
CICC Remains a Buy on Innovent Biologics (IVBXF)
Morgan Stanley Analyst forecast on MX:1801N
Jack Lin
Morgan Stanley
Morgan Stanley
$299.9
Buy
―
Reiterated
08/25/26
Jack Lin Reiterates Buy on Innovent Biologics, Citing Strong Profitability, Solid Revenue Growth, and De-Risked Late-Stage Pipeline
Guotai Haitong Analyst forecast on MX:1801N
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
$259.38
Buy
―
Reiterated
08/25/26
Guotai Haitong Remains a Buy on Innovent Biologics (IVBXF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARWRArrowhead Pharmaceuticals
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
AXGNAxoGen
HITIHigh Tide
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innovent Biologics

3 Months
Jill WuCMB International Securities
Success Rate
8/14 ratings generated profit
57%
Average Return
+11.16%
Copying Jill Wu's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +11.16% per trade.
1 Year
Rebecca LiangBernstein
Success Rate
11/12 ratings generated profit
92%
Average Return
+35.93%
Copying Rebecca Liang's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +35.93% per trade.
2 Years
Rebecca LiangBernstein
Success Rate
11/12 ratings generated profit
92%
Average Return
+70.76%
Copying Rebecca Liang's trades and holding each position for 2 Years would result in 91.67% of your transactions generating a profit, with an average return of +70.76% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1801N Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
9
10
11
6
3
Buy
12
8
8
24
24
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
18
19
30
27
In the current month, 1801N has received 27 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1801N average Analyst price target in the past 3 months is 288.92.
Each month's total comprises the sum of three months' worth of ratings.

1801N Financial Forecast

1801N Earnings Forecast

Next quarter’s earnings estimate for 1801N is $2.88 with a range of $2.88 to $2.88. The previous quarter’s EPS was $1.77. 1801N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1801N has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1801N is $2.88 with a range of $2.88 to $2.88. The previous quarter’s EPS was $1.77. 1801N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1801N has Performed in-line its overall industry.

1801N Sales Forecast

Next quarter’s sales forecast for 1801N is $25.71B with a range of $23.37B to $28.04B. The previous quarter’s sales results were $21.31B. 1801N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1801N has Performed in-line its overall industry.
Next quarter’s sales forecast for 1801N is $25.71B with a range of $23.37B to $28.04B. The previous quarter’s sales results were $21.31B. 1801N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1801N has Performed in-line its overall industry.

1801N Stock Forecast FAQ

What is MX:1801N’s average 12-month price target, according to analysts?
Based on analyst ratings, Innovent Biologics’s 12-month average price target is 288.92.
    What is MX:1801N’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:1801N, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Innovent Biologics a Buy, Sell or Hold?
        Innovent Biologics has a consensus rating of Strong Buy, which is based on 20 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Innovent Biologics’s share price target?
          The average share price target for Innovent Biologics is 288.92. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $325.29 ,and the lowest forecast is $242.52. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Innovent Biologics?
            Innovent Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
              How can I buy shares of Innovent Biologics?
              To buy shares of MX:1801N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.